Additive preventive effect of influenza and pneumococcal vaccines in the elderly Results of a large cohort study

Human Vaccines and Immunotherapeutics

Volumn 9, Issue 1, 2013, Pages 128-135

  Mahamat, Aba ^a,b   Daurès, Jean Pierre ^b,c   De Wazières, Benoît ^c  

^a CENTRE HOSPITALIER DE CAYENNE   (French Guiana)

^b UNIV MONTPELLIER   (France)

^c DEPARTMENT OF NEUROLOGY   (France)

Author keywords

23 valent pneumococcal capsular polysaccharide vaccine; Additive effect; Cohort study; Elderly; Influenza vaccine; Treatment outcome

Indexed keywords

ANTIBIOTIC AGENT; INFLUENZA VACCINE; PNEUMOCOCCUS VACCINE;

AGED; AGING; ANTIBIOTIC THERAPY; ARTICLE; CAUSE OF DEATH; CHRONIC DISEASE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG POTENTIATION; DRUG UTILIZATION; FEMALE; FRANCE; HUMAN; INFLUENZA VACCINATION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORTALITY; PILOT STUDY; RESIDENTIAL AREA; RISK REDUCTION; SEASONAL VARIATION;

23-VALENT PNEUMOCOCCAL CAPSULAR POLYSACCHARIDE VACCINE; ADDITIVE EFFECT; COHORT STUDY; ELDERLY; INFLUENZA VACCINE; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; COHORT STUDIES; DRUG UTILIZATION; FEMALE; FRANCE; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; SURVIVAL ANALYSIS;

EID: 84874745677     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.22550     Document Type: Article

References (40)

1. World Health Organization. Influenza vaccines. Wkly Epidemiol Rec 2005; 80(33): 279-87. Available: http://www.who.int/wer. Accessed: 01 October 2012.
2. Centers for Disease Control and Prevention (CDC). Estimates of deaths associated with seasonal influenza -United States, 1976-2007. MMWR Morb Mortal Wkly Rep 2010; 59:1057-62; http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5933a1. htm. Accessed 01October 2012; PMID:20798667.
3. Fiore AE, Shay DK, Haber P, Iskander JK, Uyeki TM, Mootrey G, et al.; Advisory Committee on Immunization Practices (ACIP), Centers for Disease Control and Prevention (CDC). Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2007. MMWR Recomm Rep 2007; 56(RR-6):1-54; http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5606a1. htm. Accessed 01 October 2012; PMID:17625497.
4. Vaccination schedule for 2005. Recommendations from the "Conseil supérieur d'hygiène publique de France." BEH 2005; 29-30:142-56.
5. Lina B, Holm MV, Szucs TD. Evolution of influenza vaccination coverage in France from 2001 to 2006. Med Mal Infect 2008; 38:125-32; PMID:18191520; http://dx.doi.org/10.1016/j.medmal.2007.11.014.
6. Vaux S, Van Cauteren D, Guthmann JP, Le Strat Y, Vaillant V, de Valk H, et al. Influenza vaccination coverage against seasonal and pandemic influenza and their determinants in France: a cross-sectional survey. BMC Public Health 2011; 11:30; PMID:21226919; http://dx.doi.org/10.1186/1471-2458-11-30.
7. Ortqvist A, Hedlund J, Kalin M. Streptococcus pneumoniae: epidemiology, risk factors, and clinical features. Semin Respir Crit Care Med 2005; 26:563-74; PMID:16388428; http://dx.doi.org/10.1055/s-2005-925523.
8. World Health Organization. Global surveillance for severe acute respiratory syndrome (SARS). Wkly Epidemiol Rec 2003; 78(14):110-19. Available: http://www.who.int/wer. Accessed: 18 December 2011.
9. Rosenheim M. Comité technique des vaccinations. Rapport. Efficacité du vaccin polysaccharidique pneumococcique chez les sujets âgés. 2002 [Article in French] Available: http://www.hcsp.fr/ docspdf/cshpf/r- mt-021212-rapport.pdf. Accessed 01 October 2012.
10. Assendelf WJ, Scholten RJPM, Offringa M. Pneumococcal vaccination for the elderly in The Netherlands? Assessment of the quality and content of available comparative studies. Neth J Med 2004; 62:36-44; PMID:15127829.
11. Sims RV, Steinmann WC, McConville JH, King LR, Zwick WC, Schwartz JS. The clinical effectiveness of pneumococcal vaccine in the elderly. Ann Intern Med 1988; 108:653-7; PMID:3358567.
12. Farr BM, Johnston BL, Cobb DK, Fisch MJ, Germanson TP, Adal KA, et al. Preventing pneumococcal bacteremia in patients at risk. Results of a matched case-control study. Arch Intern Med 1995; 155:2336-40; PMID:7487259; http://dx.doi.org/10.1001/archinte.1995.00430210086013.
13. Vila-Córcoles A, Ochoa-Gondar O, Hospital I, Ansa X, Vilanova A, Rodríguez T, et al.; EVAN Study Group. Protective effects of the 23-valent pneumococcal polysaccharide vaccine in the elderly population: the EVAN-65 study. Clin Infect Dis 2006; 43:860-8; PMID:16941367; http://dx.doi.org/10.1086/507340.
14. Domínguez A, Izquierdo C, Salleras L, Ruiz L, Sousa D, Bayas JM, et al.; Working Group for the Study of Prevention of CAP in the Elderly. Effectiveness of the pneumococcal polysaccharide vaccine in preventing pneumonia in the elderly. Eur Respir J 2010; 36:608-14; PMID:20075048; http://dx.doi.org/10.1183/09031936.00171309.
15. Butler JC, Breiman RF, Campbell JF, Lipman HB, Broome CV, Facklam RR. Pneumococcal polysaccharide vaccine efficacy. An evaluation of current recommendations. JAMA 1993; 270:1826-31; PMID:8411526; http://dx.doi.org/10. 1001/jama.1993.03510150060030.
16. Nichol KL, Baken L, Wuorenma J, Nelson A. The health and economic benefits associated with pneumococcal vaccination of elderly persons with chronic lung disease. Arch Intern Med 1999; 159:2437-42; PMID:10665892; http://dx.doi.org/10.1001/archinte.159.20.2437.
17. Ansaldi F, Turello V, Lai P, Bastone G, De Luca S, Rosselli R, et al. Effectiveness of a 23-valent polysaccharide vaccine in preventing pneumonia and noninvasive pneumococcal infection in elderly people: a large-scale retrospective cohort study. J Int Med Res 2005; 33:490-500; PMID:16222881.
18. Alfageme I, Vazquez R, Reyes N, Muñoz J, Fernández A, Hernandez M, et al. Clinical efficacy of antipneumococcal vaccination in patients with COPD. Thorax 2006; 61:189-95; PMID:16227328; http://dx.doi.org/10. 1136/thx.2005.043323.
19. Gaillat J, Zmirou D, Mallaret MR, Rouhan D, Bru JP, Stahl JP, et al. Clinical trial of an antipneumococcal vaccine in elderly subjects living in institutions. Rev Epidemiol Sante Publique 1985; 33:437-44; PMID:3914014.
20. Simberkoff MS, Cross AP, Al-Ibrahim M, Baltch AL, Geiseler PJ, Nadler J, et al. Efficacy of pneumococcal vaccine in high-risk patients. Results of a Veterans Administration Cooperative Study. N Engl J Med 1986; 315:1318-27; PMID:3534568; http://dx.doi.org/10.1056/NEJM198611203152104.
21. Koivula I, Stén M, Leinonen M, Mäkelä PH. Clinical efficacy of pneumococcal vaccine in the elderly: a randomized, single-blind population-based trial. Am J Med 1997; 103:281-90; PMID:9382120; http://dx.doi.org/10.1016/S0002-9343(97)00149-6.
22. Ortqvist A, Hedlund J, Burman LA, Elbel E, Höfer M, Leinonen M, et al.; Swedish Pneumococcal Vaccination Study Group. Randomised trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people. Lancet 1998; 351:399-403; PMID:9482293; http://dx.doi.org/10.1016/S0140-6736(97)07358-3.
23. Maruyama T, Taguchi O, Niederman MS, Morser J, Kobayashi H, Kobayashi T, et al. Efficacy of 23-valent pneumococcal vaccine in preventing pneumonia and improving survival in nursing home residents: double blind, randomised and placebo controlled trial. BMJ 2010; 340:c1004; PMID:20211953; http://dx.doi.org/10.1136/bmj.c1004.
24. Dubois G. Pneumococcal vaccination in France among adults. Bull Acad Natl Med 2002; 186:1461-76, discussion 1476-7; PMID:12669362.
25. Risso K, Naqvi A, Pillet S, Leplatois A, Pulcini C. Insufficient pneumococcal vaccine coverage in adult inpatients at risk. Med Mal Infect 2010; 40:341-6; PMID:20079590; http://dx.doi.org/10.1016/j.medmal. 2009.12.004.
26. Kuster SP, Tuite AR, Kwong JC, McGeer A, Fisman DN; Toronto Invasive Bacterial Diseases Network Investigators. Evaluation of coseasonality of influenza and invasive pneumococcal disease: results from prospective surveillance. PLoS Med 2011; 8:e1001042; PMID:21687693; http://dx.doi.org/10. 1371/journal. pmed.1001042.
27. Hedlund J, Christenson B, Lundbergh P, Ortqvist A. Effects of a large-scale intervention with influenza and 23-valent pneumococcal vaccines in elderly people: a 1-year follow-up. Vaccine 2003; 21:3906-11; PMID:12922125; http://dx.doi.org/10.1016/S0264-410X(03)00296-2.
28. Christenson B, Hedlund J, Lundbergh P, Ortqvist A. Additive preventive effect of influenza and pneumococcal vaccines in elderly persons. Eur Respir J 2004; 23:363-8; PMID:15065822; http://dx.doi.org/10.118 3/09031936.04.00063504.
29. Chang YC, Chou YJ, Liu JY, Yeh TF, Huang N. Additive benefits of pneumococcal and influenza vaccines among elderly persons aged 75 years or older in Taiwan-a representative population-based comparative study. [Epub ahead of print]. J Infect 2012; 65:231-8; PMID:22561486; http://dx.doi.org/10.1016/j. jinf.2012.04.014.
30. Gilchrist SA, Nanni A, Levine O. Benefits and effectiveness of administering pneumococcal polysaccharide vaccine with seasonal influenza vaccine: an approach for policymakers. Am J Public Health 2012; 102:596-605; PMID:22397339; http://dx.doi.org/10.2105/AJPH.2011.300512.
31. Clayton TC, Thompson M, Meade TW. Recent respiratory infection and risk of cardiovascular disease: casecontrol study through a general practice database. Eur Heart J 2008; 29:96-103; PMID:18063596; http://dx.doi.org/10.1093/ eurheartj/ehm516.
32. Sin DD, Wu L, Man SF. The relationship between reduced lung function and cardiovascular mortality: a population-based study and a systematic review of the literature. Chest 2005; 127:1952-9; PMID:15947307; http://dx.doi.org/10. 1378/chest.127.6.1952.
33. World Health Organization. Recommended composition of influenza virus vaccines for use in 2005/2006-influenza season. Wkly Epidemiol Rec 2005; 80(8): 71-. Available: http://www.who.int/wer. Accessed: 01 October 2012.
34. Blank PR, Schwenkglenks M, Szucs TD. Vaccination coverage rates in eleven European countries during two consecutive influenza seasons. J Infect 2009; 58:446-58; PMID:19446340; http://dx.doi.org/10.1016/j.jinf.2009.04.001.
35. Blank PR, Schwenkglenks M, Szucs TD. Influenza vaccination coverage rates in five European countries during season 2006/07 and trends over six consecutive seasons. BMC Public Health 2008; 8:272; PMID:18673545; http://dx.doi.org/10.1186/1471-2458-8-272.
36. Mullooly JP, Bennett MD, Hornbrook MC, Barker WH, Williams WW, Patriarca PA, et al. Influenza vaccination programs for elderly persons: cost-effectiveness in a health maintenance organization. Ann Intern Med 1994; 121:947-52; PMID:7978721.
37. Fedson DS, Wajda A, Nicol JP, Hammond GW, Kaiser DL, Roos LL. Clinical effectiveness of influenza vaccination in Manitoba. [Erratum in: JAMA 1994; 271] [20]. JAMA 1993; 270:1956-61; PMID:8411553; http://dx.doi.org/10.1001/jama. 1993.03510160074032.
38. Nichol KL, Margolis KL, Wuorenma J, Von Sternberg T. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. N Engl J Med 1994; 331:778-84; PMID:8065407; http://dx.doi.org/10.1056/NEJM199409223311206.
39. Gross PA, Hermogenes AW, Sacks HS, Lau J, Levandowski RA. The efficacy of influenza vaccine in elderly persons. A meta-analysis and review of the literature. Ann Intern Med 1995; 123:518-27; PMID:7661497.
40. Jefferson T, Rivetti D, Rivetti A, Rudin M, Di Pietrantonj C, Demicheli V. Efficacy and effectiveness of influenza vaccines in elderly people: a systematic review. Lancet 2005; 366:1165-74; PMID:16198765; http://dx.doi.org/ 10.1016/S0140-6736(05)67339-4.